Literature DB >> 20719466

Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques.

Alessandra Bitto1, Giovanni De Caridi, Francesca Polito, Margherita Calò, Natasha Irrera, Domenica Altavilla, Francesco Spinelli, Francesco Squadrito.   

Abstract

OBJECTIVE: Apoptosis and inflammation are important features of atherosclerotic plaques. We investigated whether a common signal molecule can trigger these two apparently separate pathways. Hypoxia inducible factor (HIF-1α) is known to participate in atherosclerosis and to stimulate apoptosis signal-regulating kinase 1 (ASK-1), one of the mitogen-activated protein kinases, which is activated by various extracellular stimuli and involved in a variety of cellular function.
METHODS: We tested carotid artery specimens from 50 subjects who underwent angioplasty and five age-matched controls for either Western blot or histologic analysis. The hypoxic status was investigated by means of HIF-1α expression in carotid specimens.
RESULTS: HIF-1α was significantly upregulated in carotid specimens with respect to controls (P < .05), ASK-1 was detected in plaques of any composition from lipidic to calcific, and this expression increased with the stage of the plaque and with the expression of inflammatory (p-ERK, RANK-L, OPG) and apoptotic molecules (caspase 9, p-p-38, and p-JNK).
CONCLUSION: Our data suggest that hypoxia is the key regulating factor that triggers inflammation as well as apoptosis in the human atherosclerotic plaque.
Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719466     DOI: 10.1016/j.jvs.2010.05.116

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

Review 2.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 3.  Frontiers in positron emission tomography imaging of the vulnerable atherosclerotic plaque.

Authors:  Mark G MacAskill; David E Newby; Adriana A S Tavares
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

4.  Perfluoroalkyl substances are inversely associated with coronary heart disease in adults with diabetes.

Authors:  Kyoko Honda-Kohmo; Robert Hutcheson; Kim E Innes; Baqiyyah N Conway
Journal:  J Diabetes Complications       Date:  2019-02-20       Impact factor: 2.852

Review 5.  Hypoxia-inducible factor signaling in vascular calcification in chronic kidney disease patients.

Authors:  Sidar Copur; Duygu Ucku; Mario Cozzolino; Mehmet Kanbay
Journal:  J Nephrol       Date:  2022-10-08       Impact factor: 4.393

Review 6.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

Review 7.  Hypoxia-inducible factor as an angiogenic master switch.

Authors:  Takuya Hashimoto; Futoshi Shibasaki
Journal:  Front Pediatr       Date:  2015-04-24       Impact factor: 3.418

8.  A mild decrease of renal function is related to increased hemoglobin level during 5-year follow-up period.

Authors:  Nara Shin; Hyunsuk Kim; Hyo Jin Kim; Miyeun Han; Sunhwa Lee; Hyungah Jo; Huh Hyuk; Ho Jun Chin
Journal:  Korean J Intern Med       Date:  2014-04-29       Impact factor: 2.884

9.  Co-culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia.

Authors:  Nirvana Sadaghianloo; Julie Contenti; Maeva Dufies; Julien Parola; Matthieu Rouleau; Shinrong Lee; Jean-François Peyron; Lucilla Fabbri; Réda Hassen-Khodja; Jacques Pouysségur; Frédéric Bost; Elixène Jean-Baptiste; Alan Dardik; Nathalie M Mazure
Journal:  J Cell Mol Med       Date:  2020-02-07       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.